135 related articles for article (PubMed ID: 14713926)
1. Lack of cross-reactivity to meropenem in a patient with an allergy to imipenem-cilastatin.
Bauer SL; Wall GC; Skoglund KJ; Peters LK
J Allergy Clin Immunol; 2004 Jan; 113(1):173-5. PubMed ID: 14713926
[No Abstract] [Full Text] [Related]
2. Safe use of meropenem in a patient with a possible nonimmediate allergy to imipenem.
Lakhal K; Lortat-Jacob B; Neukirch C; Pajot O; Wolff M
Pharmacotherapy; 2007 Sep; 27(9):1334-8. PubMed ID: 17723087
[TBL] [Abstract][Full Text] [Related]
3. Cross-reactivity and tolerability of imipenem in patients with delayed-type, cell-mediated hypersensitivity to beta-lactams.
Schiavino D; Nucera E; Lombardo C; Decinti M; Pascolini L; Altomonte G; Buonomo A; Patriarca G
Allergy; 2009 Nov; 64(11):1644-8. PubMed ID: 19392998
[TBL] [Abstract][Full Text] [Related]
4. Is it safe to use carbapenems in patients with a history of allergy to penicillin?
Sodhi M; Axtell SS; Callahan J; Shekar R
J Antimicrob Chemother; 2004 Dec; 54(6):1155-7. PubMed ID: 15486083
[TBL] [Abstract][Full Text] [Related]
5. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.
Brismar B; Malmborg AS; Tunevall G; Lindgren V; Bergman L; Mentzing LO; Nyström PO; Anséhn S; Bäckstrand B; Skau T
J Antimicrob Chemother; 1995 Jan; 35(1):139-48. PubMed ID: 7768761
[TBL] [Abstract][Full Text] [Related]
6. Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections.
Garau J; Blanquer J; Cobo L; Corcia S; Daguerre M; de Latorre FJ; León C; Del Nogal F; Net A; Rello J
Eur J Clin Microbiol Infect Dis; 1997 Nov; 16(11):789-96. PubMed ID: 9447899
[TBL] [Abstract][Full Text] [Related]
7. Incidence of imipenem hypersensitivity reactions in febrile neutropenic bone marrow transplant patients with a history of penicillin allergy.
McConnell SA; Penzak SR; Warmack TS; Anaissie EJ; Gubbins PO
Clin Infect Dis; 2000 Dec; 31(6):1512-4. PubMed ID: 11096026
[TBL] [Abstract][Full Text] [Related]
8. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
Kuo BI; Fung CP; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445
[TBL] [Abstract][Full Text] [Related]
9. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants.
Hornik CP; Herring AH; Benjamin DK; Capparelli EV; Kearns GL; van den Anker J; Cohen-Wolkowiez M; Clark RH; Smith PB;
Pediatr Infect Dis J; 2013 Jul; 32(7):748-53. PubMed ID: 23838776
[TBL] [Abstract][Full Text] [Related]
10. A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem.
Wu Y; Chen K; Shi Z; Wang Q
Curr Pharm Biotechnol; 2014; 15(8):685-90. PubMed ID: 25051950
[TBL] [Abstract][Full Text] [Related]
11. Incidence of seizures in pediatric cancer patients treated with imipenem/cilastatin.
Karadeniz C; Oğuz A; Canter B; Serdaroğlu A
Pediatr Hematol Oncol; 2000; 17(7):585-90. PubMed ID: 11033734
[TBL] [Abstract][Full Text] [Related]
12. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study.
Fabian TC; File TM; Embil JM; Krige JE; Klein S; Rose A; Melnick D; Soto NE
Surg Infect (Larchmt); 2005; 6(3):269-82. PubMed ID: 16201937
[TBL] [Abstract][Full Text] [Related]
13. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients.
Cox CE; Holloway WJ; Geckler RW
Clin Infect Dis; 1995 Jul; 21(1):86-92. PubMed ID: 7578765
[TBL] [Abstract][Full Text] [Related]
14. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.
Colardyn F; Faulkner KL
J Antimicrob Chemother; 1996 Sep; 38(3):523-37. PubMed ID: 8889726
[TBL] [Abstract][Full Text] [Related]
15. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin.
Dreetz M; Hamacher J; Eller J; Borner K; Koeppe P; Schaberg T; Lode H
Antimicrob Agents Chemother; 1996 Jan; 40(1):105-9. PubMed ID: 8787889
[TBL] [Abstract][Full Text] [Related]
16. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.
Bartoloni A; Strohmeyer M; Corti G; Buonomini MI; Franchino L; Romanelli G; Moretti AM; De Vizzi GB; Petraglia A; Mancini P; Atzeni R; Fogliani V; Giura R; Paradisi F
Drugs Exp Clin Res; 1999; 25(6):243-52. PubMed ID: 10713862
[TBL] [Abstract][Full Text] [Related]
17. A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections.
Hou F; Li J; Wu G; Zheng B; Chen Y; Gu J; Wang H; Huo L; Xue X; Jia C; Yin Y; Tian X; Ren S
Chin Med J (Engl); 2002 Dec; 115(12):1849-54. PubMed ID: 12622937
[TBL] [Abstract][Full Text] [Related]
18. Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients.
Shah PM; Heller A; Fuhr HG; Walther F; Halir S; Schaumann R; Böhme A; Jung B; Köhler A; Lips-Schulte C; Stille W
Infection; 1996; 24(6):480-4. PubMed ID: 9007599
[TBL] [Abstract][Full Text] [Related]
19. Cross-reactivity between carbapenems: two case reports.
Noguerado-Mellado B; Pinto Fernández C; Pineda-Pineda R; Martínez Lezcano P; Álvarez-Perea A; De Barrio Fernández M
J Allergy Clin Immunol Pract; 2014; 2(6):816-7. PubMed ID: 25439383
[No Abstract] [Full Text] [Related]
20. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections.
Nichols RL; Smith JW; Geckler RW; Wilson SE
South Med J; 1995 Apr; 88(4):397-404. PubMed ID: 7716590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
